AI주식인사이트AI Stock Insight
C

셀루메드

049180KOSDAQ기초 의약물질 제조업

42.0 / 100

Reference Date: 2026-04-13

Financial Score9.5 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Declined 9.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Cellumed operates in various sectors including medical devices, biologics, and cosmeceuticals, focusing on tissue engineering-based medical devices and growth factor manufacturing. The company is expanding into mRNA vaccine production enzyme development, secondary battery, and electric bicycle businesses, aiming for overseas market entry. It also diversifies through subsidiaries engaged in environmental engineering and real estate development.

Number of Employees

83people

Average Salary

48.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 27.774.0Point
PBR
9.26Industry Average 2.040.0Point

4.5x industry avg (risky)

ROE
-198.37Industry Average -2.963.5Point

67.0x industry avg (excellent)

Debt Ratio
675.03Industry Average 29.080.0Point

23.2x industry avg (risky)

Trend 2022~20242.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲6.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼124.3% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -147.7% (declining, 2yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (21%)

Current 1,009Won52-week high 2,57052-week low 570
1-month return1.0Point

1m -9.10% (falling)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

14 totalPositive 0Neutral 14Negative 0
  • Neutral사업보고서 (2025.12)2026-04-06
  • Neutral정기주주총회결과2026-03-31
  • Neutral사업보고서제출기한연장신고서 (2025.12)2026-03-23
  • Neutral주식등의대량보유상황보고서(약식)2026-03-23
  • Neutral기타경영사항(자율공시) (감사보고서 제출 지연)2026-03-23